Merck (MRK) said Thursday its late-stage trial evaluating its cancer drug Keytruda in combination with chemotherapy with or without bevacizumab met its primary endpoint of progression-free survival in patients with platinum-resistant recurrent ovarian cancer whose tumors expressed PD-L1 and in all comers.
The trial also met a secondary endpoint of overall survival in patients whose tumors express PD-L1, the company said.
The trial showed no new safety signals for Keytruda as the safety profile remained consistent with that observed in previously reported studies.
Merck said the study is continuing and that the final overall survival results for the entire study population will be evaluated at a future analysis.
The company's shares were up about 1% in recent premarket activity on Thursday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。